CytoReason, a developer of computational disease models for efficient drug discovery and development, has signed a commercial partnership with Helixrus, a Korean company focused on biological big data and multi-omics, the company announced Tuesday. The partnership will see Helixrus represent CytoReason’s unique artificial intelligence (AI) platform and professional services in the Korean market.

Read more here.